NICE has assessed the My5-FU assay to help the NHS decide whether to use this product.
The My5-FU assay is used to measure levels of 5-fluorouracil (5-FU) in blood samples of patients having 5-FU chemotherapy. These measurements may guide changes to the dose of 5-FU so it is enough to treat the cancer, but is not toxic to the patient.
NICE has recommended the My5-FU assay only for use in research for guiding changes to the 5-FU dose given during chemotherapy. The technique shows promise, and NICE recommends that more evidence on its use in NHS clinical practice is needed.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.